Dopaminergic pathways of the brain and drugs used to treat Parkinson’s Disease and Schizophrenia Flashcards
What are the three main dopaminergic pathways in the brain?
Nigrostriatal
Mesolimbic
Tuberoinfundibular system
Where are each of these pathways found?
Nigrostriatal– projecting from the substantia nigra pars compacta to the striatum
Mesolimbic– projecting from the ventral tegmental area to the nucleus accumbens, frontal cortex, limbic cortex and olfactory tubercle
Tuburoinfundibular system– projecting from the arcuate nucleus in the hypothalamus to the median eminence and pituitary gland
What are the roles of these pathways?
Nigrostriatal – control of movement
Mesolimbic – involved in emotion
Tuburoinfundibular system – regulate hormone secretion
What are the two families of dopamine receptors and which receptors fall into each of these families?
D1 family – D1 + D5
D2 family – D2, D3 + D4
Describe dopamine synthesis.
Tyrosine is converted by tyrosine hydroxylase to DOPA
DOPA is converted by DOPA decarboxylase to Dopamine
Is Parkinson’s disease more common in males or females?
Males – 4:1
What percentage of all cases of Parkinson’s disease is accounted for by familial Parkinson’s disease?
8%
The rest are idiopathic
What are the possible causes of idiopathic Parkinson’s disease?
Possibly a combination of environmental, oxidative stress, altered protein metabolism and risk genes
What are the cardinal signs of Parkinson’ disease?
Resting tremor (pill-rolling tremor)
Rigidity (stiffness – limbs feel weak and heavy)
Bradykinesia (slowness of movement)
Postural abnormality
What are the presenting symptoms of Parkinson’s disease?
Pill-rolling resting tremor
Difficulty with fine movements (micrographia)
Poverty of blinking
Hypomimic face
Monotony of speech and loss of volume of voice
Disorders of posture – flexion of the neck and trunk
Lack of arm swing
Loss of balance – lack of righting reflex, retropulsion
Short steps, shuffling gait
Describe the initial distribution of symptoms across the body.
Unilateral onset
Symptoms spread to both sides
Generally symptoms worsen with some patients becoming severely disabled
What are some non-motor symptoms of Parkinson’s disease?
Depression Pain Taste/smell disturbances Cognitive decline/dementia Autonomic dysfunction (constipation, postural hypotension, urinary frequency/urgency, impotence, increased sweating)
What is the main area of the brain that is affected by Parkinson’s disease?
Substantia nigra
Other brain areas affected: locus coeruleus, dorsal vagus nucleus, nucleus basalis of Mynert
Describe the neuropathology of Parkinson’s disease.
Putamen-projecting pathways degenerate significantly Lewy bodies (large circular structure with bright core and white surrounding, packed with alpha-synuclein) also present – this is probably a defensive mechanism to protect against toxic altered proteins
What are the stages of Parkinson’s disease?
1-2 = dorsal motor nucleus of vagus, raphe nucleus, locus coeruleus 3 = substantia nigra pars compacta 4 = amygdala, nucleus of Meynert, hippocampus 5-6 = cingulate cortex, temporal cortex, frontal cortex, parietal cortex, occipital cortex
What is the main biochemical change seen in Parkinson’s disease?
Marked reduction in the caudate nucleus/putamen dopamine content
What proportion of dopaminergic neurones of the nigrostriatal dopaminergic pathway must be lost before symptoms occur?
80-85% of dopaminergic neurones and 70% of striatal dopamine must be depleted before symptoms appear
What is the reason for this?
There are compensatory mechanisms e.g. neurone overactivity and increase in dopamine receptors
What other type of drug has to be given with L-DOPA in dopamine replacement therapy and why?
Peripheral DOPA decarboxylase inhibitor
This prevents the conversion of L-DOPA to dopamine by peripheral DOPA decarboxylase (this can cause nausea and vomiting)
State two different preparation of dopamine replacement therapy.
Sinamet = Carbodopa + L-DOPA Madopar = Benserazide + L-DOPA
What does L-DOPA treat?
Hypokinesia
Tremor
Rigidity
Describe how the dosage of L-DOPA is changed with continued treatment.
It is started low and increased until maximum benefit of drug is achieved without side effects
Effectiveness of L-DOPA declines with time